Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Jul
20
Today In Oncology
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo